Osteoporosis Prevention With Low Dose Alendronate

• Status: Completed
• Trial end date: 2012-01-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to evaluate the efficacy of the intermittent administration of alendronate in a low dose, 70 mg once every two week, as osteoporosis prevention for menopausal, osteopenic patients, who don't want or can't receive an oestrogenic substitution treatment.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital of Mont-Godinne
• Treatments: Alendronate; Calcium; Vitamin D; Vitamins

Criteria

Inclusion Criteria:

• 45 to 60 year-old women

• Menopausal since at least 6 months

• Baseline lumbar BMD from -1 till -2.5

Exclusion Criteria:

• Bone disease other than osteopenia

• Treatment with selective estrogen receptor modulator (SERMs), calcitonin or hormone replacement therapy within 6 monts prior to randomization

• Former or current treatment with any bisphosphonate or bone forming agents

• Chronic use of oral or iv corticosteroids

• Any diagnosis of malignancy less than 12 months